Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin + Anti-VEGF in Diabetic Macular Edema
NCT06845163Phase 2Completed
- Sponsor
- Alexandria University
- Start
- Feb 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin in diabetic macular edema (DME) (2 arms), sponsored by Alexandria University. Primary endpoints: Mean central subfield thickness at 3 months and Best-corrected visual acuity at 3 months. Started Feb 2025; status: completed.
02
Drugs
dapagliflozin
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT06845163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06845163.